| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w28333 |
| 来源ID | Working Paper 28333 |
| Price Indices and the Value of Innovation with Heterogenous Patients | |
| Claudio Lucarelli; Sean Nicholson; Nicholas Tilipman | |
| 发表日期 | 2021-01-11 |
| 出版年 | 2021 |
| 语种 | 英语 |
| 摘要 | Many countries use uniform cost-effectiveness criteria to determine whether to adopt a new medical technology for the entire population. This approach assumes homogeneous preferences for expected health benefits and side effects. We examine whether new prescription drugs generate welfare gains when accounting for heterogeneous preferences by constructing quality- adjusted price indices for colorectal cancer drug treatments. We find that while the efficacy gains from newer drugs do not justify high prices for the population as a whole, innovation improves the welfare of sicker, late-stage cancer patients. A uniform evaluation criterion would not permit these innovations despite welfare gains to a subpopulation. |
| 主题 | Health, Education, and Welfare ; Health ; Poverty and Wellbeing ; Industrial Organization |
| URL | https://www.nber.org/papers/w28333 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/586006 |
| 推荐引用方式 GB/T 7714 | Claudio Lucarelli,Sean Nicholson,Nicholas Tilipman. Price Indices and the Value of Innovation with Heterogenous Patients. 2021. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w28333.pdf（771KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
